PF PRISM CV FDA Approval NDA 021821

NDA 021821

PF PRISM CV

FDA Drug Application

Application #021821

Documents

Letter2005-06-21
Letter2006-07-21
Letter2007-02-02
Letter2007-04-09
Letter2009-03-25
Letter2009-03-25
Letter2009-06-30
Letter2010-07-23
Letter2013-10-01
Letter2010-07-23
Letter2013-10-01
Letter2016-06-30
Letter2016-01-21
Label2005-06-17
Label2009-03-25
Label2009-02-10
Label2009-03-25
Label2009-02-04
Label2016-06-01
Review2005-08-24
Review2014-01-16
Review2014-01-16
Letter2006-07-21
Letter2007-05-29
Letter2009-02-03
Letter2009-02-03
Letter2009-02-13
Letter2009-03-25
Letter2009-02-03
Letter2010-07-23
Letter2013-05-28
Letter2016-06-01
Label2007-04-06
Label2007-05-29
Label2009-02-04
Label2009-03-25
Label2010-07-19
Label2010-07-16
Label2013-09-27
Label2010-07-19
Label2013-09-27
Label2013-05-24
Label2016-07-14
Label2016-01-26
Other Important Information from FDA2011-12-21
Label2018-04-17
Letter2018-04-17
Label2020-01-17
Letter2020-01-17
Label2020-06-24
Letter2020-06-24

Application Sponsors

NDA 021821PF PRISM CV

Marketing Status

Prescription001

Application Products

001POWDER;INTRAVENOUS50MG/VIAL1TYGACILTIGECYCLINE

FDA Submissions

TYPE 1; Type 1 - New Molecular EntityORIG1AP2005-06-15PRIORITY
LABELING; LabelingSUPPL3AP2006-07-12STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL4AP2006-07-12N/A
LABELING; LabelingSUPPL6AP2007-01-24STANDARD
LABELING; LabelingSUPPL7AP2007-04-03STANDARD
LABELING; LabelingSUPPL10AP2007-05-18STANDARD
LABELING; LabelingSUPPL11AP2009-01-29STANDARD
EFFICACY; EfficacySUPPL13AP2009-03-20UNKNOWN
LABELING; LabelingSUPPL14AP2009-01-29STANDARD
LABELING; LabelingSUPPL16AP2009-02-10STANDARD
EFFICACY; EfficacySUPPL17AP2009-03-20UNKNOWN
EFFICACY; EfficacySUPPL18AP2009-03-20UNKNOWN
LABELING; LabelingSUPPL19AP2009-01-29STANDARD
LABELING; LabelingSUPPL21AP2010-07-16STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL22AP2009-06-26N/A
LABELING; LabelingSUPPL25AP2010-07-16UNKNOWN
LABELING; LabelingSUPPL26AP2013-09-26UNKNOWN
LABELING; LabelingSUPPL27AP2010-07-16UNKNOWN
LABELING; LabelingSUPPL31AP2013-09-26STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL36AP2014-01-09PRIORITY
LABELING; LabelingSUPPL37AP2013-05-23STANDARD
LABELING; LabelingSUPPL39AP2016-05-31STANDARD
LABELING; LabelingSUPPL42AP2016-06-29STANDARD Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs.
LABELING; LabelingSUPPL43AP2016-01-19STANDARD
LABELING; LabelingSUPPL45AP2018-04-16STANDARD
LABELING; LabelingSUPPL48AP2020-01-16STANDARD
LABELING; LabelingSUPPL49AP2020-06-23STANDARD

Submissions Property Types

SUPPL21Null7
SUPPL25Null6
SUPPL26Null6
SUPPL27Null6
SUPPL31Null6
SUPPL36Null0
SUPPL37Null15
SUPPL39Null15
SUPPL42Null7
SUPPL43Null7
SUPPL45Null7
SUPPL48Null6
SUPPL49Null6

TE Codes

001PrescriptionAP

CDER Filings

cder:Array
(
    [0] => Array
        (
            [ApplNo] => 21821
            [companyName] => 
            [docInserts] => ["",""]
            [products] => []
            [labels] => 
            [originalApprovals] => []
            [supplements] => 
            [actionDate] => 0000-00-00
        )

)

© 2026 FDA.report
This site is not affiliated with or endorsed by the FDA.